The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
[AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione NADP binds to AKR1B1 protein binds to fidarestat NADP results in increased activity of AKR1B1 protein
[AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione NADP results in increased activity of AKR1B10 protein NADP binds to AKR1B10 protein mutant form binds to fidarestat AKR1B10 protein results in decreased reduction of NADP
[AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone]
[AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]
[AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone]
[AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone
[[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes
[AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]
[ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde NADP results in increased activity of ALDH3A1 protein
[diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein]
[CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein
CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide] [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein
[CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog
[CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein]
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein]
[CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine] [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein
NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein]
[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]
[NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein
CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]
NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]]
NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein] GSR protein results in increased oxidation of NADP caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP] Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]
NADP binds to and results in increased activity of HSD11B1 protein HSD11B1 protein results in increased reduction of NADP Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]
[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein] NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein
[Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein
[22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein
IDH2 protein mutant form results in increased abundance of NADP Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
NADP binds to KCNAB2 protein [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
[Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
[3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]
[Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein
NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3] [POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP] [POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]
[NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein] [Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]
[PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
TALDO1 gene mutant form results in decreased abundance of NADP Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]
NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein] TIGAR protein results in increased abundance of NADP NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein] NADP results in increased reduction of TXNRD1 protein [Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [Arsenic Trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]
CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]
NAADP results in increased activity of MCOLN1 protein [NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium
browse the term
